PDCD1 and neoplasm: Taken together, these results suggest that T cells in the STM2457 treated tumour microenvironment undergo significant cell proliferation and activation, indicating that METTL3 inhibition potentiate anti‐PD‐1 therapy by improving T‐cell persistence.